Investor Relations

Press Releases

Oxitec CEO to testify before Congressional Committee on May 25th

Oxitec CEO Hadyn Parry will testify on Wednesday, May 25th at 10:15 a.m. ET before the United States House Committee on Science, Space and Technology about the role genetically engineered mosquitos can play in controlling the spread of the Aedes aegypti mosquito, a known carrier of the Zika virus. 

Oxitec has pioneered a genetically engineered male mosquito with a self-limiting gene. Trials in Brazil, Panama and the Cayman Islands have demonstrated that Oxitec’s technology produces an unparalleled reduction in the population of the dangerous Aedes aegypti mosquito. The Food & Drug Administration recently concluded a public comment period after issuing a preliminary finding of no significant impact in support of a field study of Oxitec’s solution in Key Haven, Fla.   

WHO:  Hadyn Parry, CEO, Oxitec, Ltd.

WHAT:  Testifying before the U.S. House Committee on Science, Space and Technology about the role an Oxitec engineered male mosquito can play in controling the spread of the Aedes aegypti mosquito, a known carrier of the Zika virus.

WHEN:  Wednesday, May 25, 2016 at 10:15 a.m. ET

WHERE:  2318 Rayburn House Office Building, Washington, DC

About Oxitec
Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.

Press contact:

For more information:

Oxitec:
Matt Warren
info@oxitec.com
+44 (0) 1235 832393

Site: www.oxitec.com
Facebook: www.facebook.com/oxitec
Twitter: www.twitter.com/oxitec